187 related articles for article (PubMed ID: 38003694)
1. Resensitizing Paclitaxel-Resistant Ovarian Cancer via Targeting Lipid Metabolism Key Enzymes CPT1A, SCD and FASN.
Ma Q; Liu Z; Wang T; Zhao P; Liu M; Wang Y; Zhao W; Yuan Y; Li S
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003694
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
Dai C; Xu P; Liu S; Xu S; Xu J; Fu Z; Cao J; Lv M; Zhou J; Liu G; Zhang H; Jia X
Arch Gynecol Obstet; 2021 May; 303(5):1271-1281. PubMed ID: 33151424
[TBL] [Abstract][Full Text] [Related]
3. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
4. Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M; Zhang S; Ma Y; Yang Y; An R
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33846814
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer.
He J; Shi XY; Li ZM; Pan XH; Li ZL; Chen Y; Yan SJ; Xiao L
BMC Mol Cell Biol; 2019 Nov; 20(1):49. PubMed ID: 31718559
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
7. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
[TBL] [Abstract][Full Text] [Related]
8. SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
Shi Y; Zhang J; Liu M; Huang Y; Yin L
J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
[TBL] [Abstract][Full Text] [Related]
9. The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes.
Seborova K; Kloudova-Spalenkova A; Koucka K; Holy P; Ehrlichova M; Wang C; Ojima I; Voleska I; Daniel P; Balusikova K; Jelinek M; Kovar J; Rob L; Hruda M; Mrhalova M; Soucek P; Vaclavikova R
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008510
[TBL] [Abstract][Full Text] [Related]
10. CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
[TBL] [Abstract][Full Text] [Related]
11. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of Cofilin-1 Enhances Paclitaxel Resistance of Epithelial Ovarian Cancer Cells by Inhibiting Apoptosis.
Li M; Dong XD; Lyu QB; Zhang W; Huang S; Yang CX; Cui D; Lai HY
Biomed Environ Sci; 2021 Jun; 34(6):465-477. PubMed ID: 34284854
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.
Veigel D; Wagner R; Stübiger G; Wuczkowski M; Filipits M; Horvat R; Benhamú B; López-Rodríguez ML; Leisser A; Valent P; Grusch M; Hegardt FG; García J; Serra D; Auersperg N; Colomer R; Grunt TW
Int J Cancer; 2015 May; 136(9):2078-90. PubMed ID: 25302649
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
18. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
20. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
Shuang T; Wang M; Shi C; Zhou Y; Wang D
FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]